- ElevateBio BaseCamp to support anticipated TC-210 Phase 2 clinical trial demand CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients suffering from cancer, today announced that the Comp Read more...
New York, USA, June 15, 2021 (GLOBE NEWSWIRE) -- According to a recent report offered by Research Dive, the Read more...
New York, USA, Nov. 15, 2021 (GLOBE NEWSWIRE) -- A new report on the global social me Read more...
